Physicians' Academy for Cardiovascular Education

Perspectives on Aim High

3' education - July 22, 2011

AIM-HIGH

Recently, the AIM-HIGH trial (Atherothrombosis Intervention in Metabolic Syndrome with Low HDL/High Triglyceride and Impact on Global Health Outcomes) was halted prematurely, 18 months ahead of schedule, because niacin offered no additional benefits in this patient population.

During a recently held PACE Lipid Master Class Professor John Betteridge (University College London, United Kingdom) discussed the background and probable shortcomings of this trial with Professor Jane Armitage (Clinical Trials Service Unit, University of Oxford, United Kingdom) during a video interview.

They also discussed another trial, the HPS2-THRIVE (Heart Protection Study 2 – Treating HDL to Reduce Vascular Events), another large, ongoing trial randomized in a similar sort of way. The results of that trial are expected towards the end of 2012.

Questions to be addressed in this PACE expert opinion are:
  • Halting the AIM-HIGH trial – What does this imply?
  • The AIM-HIGH trial: What is the background of this trial?
  • The AIM-HIGH trial: What might be the reason for halting the trial?
  • What about the dose of niacin: Could the expected results be detected with this dose?
  • Studying the effects of niacin: What other trial is ongoing?


View prof Betteridge in discussion with prof Armitage


About the speakers

Prof. D John Betteridge,
Consultant Physician, University College London Hospitals, London, UK, Emeritus Professor of Endocrinology and Metabolism University College London, and Associate Dean Royal Society of Medicine.

Prof Jane Armitage,
Professor of Clinical Trials and Epidemiology and Honorary Consultant in Public Health Medicine at the University of Oxford, United Kingdom

View the Powerpoint slides presented

AIM-HIGH: Rationale
AIM-HIGH: Study design
Nicotinic Acid: Treatment of Dyslipidemia and Atherosclerosis
HPS2-THRIVE (Heart Protection Study 2 – Treating HDL to Reduce Vascular Events)

Share this page with your colleagues and friends: